Botanical Capsule Claims in the US, EU and Australia: What Each Market Lets a Label Say
Compliance snapshot
- The United States lets a botanical capsule carry a structure/function claim without pre-approval. The brand owner must hold substantiation, print the standard disclaimer, and notify the FDA within 30 days of first marketing the product (21 CFR 101.93).
- The EU works the other way round. A health claim is usable only if it is authorised, and the Commission’s register lists claims that are authorised or refused. Health claims that refer to botanical substances are still held outside the register while assessment is unfinished.
- Australia sits between the two. A listed medicine (AUST L) draws its indications from a permitted list, and the sponsor certifies it holds the evidence. An assessed listed medicine (AUST L(A)) has its efficacy checked by the TGA.
- The claim you want decides what the capsule specification has to prove: assay, botanical identity, contaminant limits, dose per serving. Market registration and claim notification sit with the brand owner in every case.
- Silk Foods Ceylon (SFC) fills capsules at 100,000 per shift under BRCGS and FSSC 22000 V6, with the capsule MOQ confirmed on your quote.
A brand team often arrives at a capsule brief with the claim already written: “supports immune health”, “for joint comfort”. The manufacturer’s job is then to find out whether that sentence can legally sit on a label in the target market, and what the product has to prove for it to stay there. The answer differs in the US, the EU and Australia, and it differs in kind, not just in wording. This piece is for nutraceutical and wellness brand buyers writing a private-label brief for any of the three. It is a procurement briefing, not legal advice, and a regulatory adviser in the target market should check the final label.
What does the US allow a supplement label to say?
A dietary supplement label in the US may carry a structure/function claim, a statement about how an ingredient affects the normal structure or function of the body, without FDA approval of the wording. Three conditions apply. The firm must have substantiation that the claim is truthful and not misleading. The label must carry the prescribed disclaimer. And the firm must notify the FDA within 30 days after it first markets the product with the claim.
The disclaimer is fixed in 21 CFR 101.93: “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.” It must sit next to the claim, or be linked to it with a symbol such as an asterisk, in bold type of at least one-sixteenth of an inch. The FDA, in its own guidance, notes that it generally sends no reply to a notification it does not object to, so silence is not approval.
The hard edge is the disease claim. A statement that a product diagnoses, treats or prevents a disease makes it a drug under the regulation, whatever the capsule contains. “Supports healthy blood sugar levels” is a different sentence from “lowers blood sugar in diabetes”, and the second one is where a botanical brief goes wrong. The cinnamon capsule claim guide works through that boundary for one ingredient.
How does the EU treat a health claim on a botanical?
The EU runs a positive list. Under Regulation (EC) No 1924/2006, a health claim may be used only if it has been authorised, and the European Commission publishes a searchable register that shows authorised claims with their conditions of use and non-authorised claims with the reasons they were refused. The register is described by the Commission as information only, so the legal act behind each entry is the controlling text.
Botanicals are the awkward case. The Commission states that health claims referring to botanical substances are excluded from the register while their assessment is unfinished, and are listed in a separate pending document. In practice, a capsule built on turmeric, ashwagandha or moringa often has no authorised health claim to point to, even when the same ingredient is sold in the US with a structure/function line. Buyers who assume a US claim travels to Europe find this out late and at some cost.
A brand in this position has three honest options: use only claims that appear as authorised for a nutrient in the formula (a vitamin or mineral carried alongside the botanical), sell the botanical with no health claim and let the ingredient name and dose carry the label, or apply for authorisation, which is slow and expensive. The EU botanical sourcing guide covers the MRL and novel food rules that sit beside claims.
A procurement-side observation
The SRV procurement desk sees one brief pattern again and again: a brand writes one claim, builds one label, and plans to ship the same capsule to three markets. The capsule often can. The label rarely can. The decision that saves money is made before the first sample: which market sets the tightest claim, and does the brand accept writing every other market’s label down to it.
What does Australia’s listed medicine pathway require?
In Australia a botanical capsule is generally a complementary medicine, not a food. A standard listed medicine carries an AUST L number. It is not assessed by the Therapeutic Goods Administration (TGA) before listing. The sponsor, the Australian entity that holds the listing, certifies safety, quality and efficacy, and the indications must be chosen from the permitted indications list. At listing, the sponsor certifies that it holds evidence to support each indication it uses.
An assessed listed medicine (AUST L(A)) adds a TGA assessment of efficacy before listing. The TGA says such a product may then carry a statement that its efficacy has been assessed. Its evidence guidance says every indication must be supported by scientific evidence, and that an indication resting on traditional use alone is not acceptable for this route. For a brand whose story is traditional Ayurvedic use, that is a meaningful limit. A traditional-use indication can sit on a standard listing but not on an assessed one.
Ingredients matter too, because a listed medicine may use only permitted ingredients. Buyers should check the botanical against the TGA’s permitted ingredient rules before the brief is final. The Australian import side, covering biosecurity and labelling for Ceylon ingredients, is set out in importing Ceylon spices into Australia.
How do the three markets compare?
The table puts the three side by side on the points a capsule brief actually turns on.
| Question | United States | European Union | Australia |
|---|---|---|---|
| Default legal status | Dietary supplement (food category) | Food supplement | Listed complementary medicine |
| Pre-market approval of claim | None | Claim must be authorised | None for AUST L; TGA efficacy check for AUST L(A) |
| Where the claim comes from | Brand writes a structure/function claim | Authorised register entry | Permitted indications list |
| Notification or listing | Notify FDA within 30 days of first marketing | Per member state rules | Listing with an Australian sponsor |
| Fixed label wording | Prescribed disclaimer | Authorised wording and conditions of use | Indication wording and listing number |
| Evidence behind the claim | Substantiation held by the brand | Dossier behind the authorisation | Sponsor-held evidence; scientific evidence only for AUST L(A) |
| Botanical claims | Allowed if substantiated, no disease claims | Botanical health claims on hold | Allowed if indication and ingredient are permitted |
Read across the rows and one fact stands out. The same turmeric capsule can be claimed three different ways, or not claimed at all, depending on which row of the table the label is written to.
How does the claim change what the capsule specification must prove?
Every claim is a promise about what is in the capsule. The specification has to make that promise checkable, batch after batch, and the claim you choose sets how tight the checks must be. A few lines change most often.
- Botanical identity. The species and plant part named on the label must match the powder. A leaf and a root of the same genus are different ingredients, as the ashwagandha root versus leaf comparison shows for a capsule brief.
- Marker assay. A label that names a compound or a standardised level needs an assay method and a range on the certificate of analysis. The turmeric capsule guide shows how a curcuminoid figure is written into a spec.
- Dose per serving. The claim is made at a dose. The fill weight, the number of capsules per day and the bottle count must agree, which is the arithmetic in the capsule size and fill weight article.
- Contaminant and microbial limits. These follow the destination market rather than the claim, but a claim that invites regulator attention makes a clean certificate of analysis more valuable.
- Documents. The brand owner needs the supplier’s certificate per batch and a statement of botanical origin to build the substantiation file the US and Australian routes expect.
Where the Silk Route Ventures model doesn’t fit
A brand that wants the supplier to hold the market registration, file the FDA notification, or act as the Australian sponsor. Those responsibilities belong to the brand owner, and no manufacturer should promise to carry them. A brand that wants a disease claim on a food-category capsule will also not find a compliant route here.
Which markets should a first brief target?
A practical order for a first private-label capsule is the US, then Australia, then the EU, driven by how much the claim can say at the start. The US allows the widest structure/function wording at the lowest entry cost. Australia needs a listing but the standard route is self-certified. The EU is the strictest for botanicals, so a brand that writes its label to EU rules first can usually carry that label elsewhere with little change.
Whatever order you choose, put the target market on the first page of the brief. A capsule built for one market is a short R&D job. A capsule built to satisfy all three at once is a longer conversation about claims, and the private-label botanical capsule timeline shows where that time falls. Botanical supply for these capsules comes from the Sri Lankan herbs range, and the turmeric capsules SKU is a practical template for a first spec.
Frequently asked questions
Do I need FDA approval to put a structure/function claim on a botanical capsule?
No. The US does not approve structure/function claims in advance. The brand owner must hold substantiation, print the prescribed disclaimer beside the claim, and notify the FDA within 30 days after first marketing the product. A claim that a product treats or prevents a disease is a drug claim and falls outside this route.
Can I use a US structure/function claim on a botanical capsule sold in the EU?
Not automatically. EU health claims must be authorised, and the Commission holds health claims that refer to botanical substances outside its register while assessment is unfinished. Many botanical claims that are lawful in the US therefore have no EU equivalent. Check the register entry, or sell with no health claim, before printing the label.
What is the difference between AUST L and AUST L(A) in Australia?
An AUST L medicine is listed without TGA assessment, using permitted indications, with the sponsor certifying it holds the evidence. An AUST L(A) medicine has its efficacy assessed by the TGA before listing and may state that it was assessed. Traditional-use evidence alone is not accepted for AUST L(A) indications.
Does Silk Route Ventures make private-label botanical capsules for the US, EU and Australian markets?
Yes, as the manufacturer. Silk Foods Ceylon fills capsules at 100,000 per shift in Matale under BRCGS and FSSC 22000 V6, with the capsule MOQ confirmed on your quote. The R&D and NPD team develops custom blends within 3 to 4 weeks at most. Claim notification and market registration stay with the brand owner.
How Silk Route Ventures can help
Silk Route Ventures (SRV) manufactures nutraceutical capsules and supplies bulk Ayurvedic and functional botanicals to wellness brands globally. The Silk Foods Ceylon facility in Matale holds BRCGS and FSSC 22000 V6, with USDA Organic and EU Organic on the relevant SKUs. The capsule MOQ is confirmed on your quote, samples are free for evaluation (you cover the courier), and the R&D and NPD team develops custom blends within 3 to 4 weeks at most. For a new capsule, the useful first step is to send the botanical, the dose per day, the draft claim and the target market, so the trade desk can propose a specification that supports the claim and a certificate of analysis to match. Contact us to send an inquiry or request a sample.
Sources
- U.S. Food and Drug Administration, Structure/Function Claims and Notifications for Structure/Function and Related Claims in Dietary Supplement Labeling (notification within 30 days of first marketing; substantiation; disease claims). https://www.fda.gov/food/nutrition-food-labeling-and-critical-foods/structurefunction-claims (retrieved 17 October 2026)
- Code of Federal Regulations, Title 21, section 101.93, Certain types of statements for dietary supplements (disclaimer wording, placement and type size). https://www.law.cornell.edu/cfr/text/21/101.93 (retrieved 17 October 2026)
- European Commission, EU Register of nutrition and health claims, under Regulation (EC) No 1924/2006 (authorised and non-authorised claims; botanical health claims held pending). https://food.ec.europa.eu/food-safety/labelling-and-nutrition/nutrition-and-health-claims/eu-register-health-claims_en (retrieved 17 October 2026)
- Therapeutic Goods Administration, Understanding listed and registered complementary medicine regulation, and Assessed listed medicines evidence guidelines (AUST L, AUST L(A), permitted indications, evidence for indications). https://www.tga.gov.au/resources/guidance/understanding-listed-and-registered-complementary-medicine-regulation (retrieved 17 October 2026)
Written by the Silk Route Ventures Trade Team. Silk Route Ventures (E-Silk Route Ventures (Pvt) Ltd) is a Sri Lankan B2B supply-chain operator for the Food, Beverage, Wellness, and Nutraceuticals sectors. The Silk Foods Ceylon manufacturing arm holds BRCGS and FSSC 22000 V6 certifications. Questions or to request a sample: Contact us or email info@esilkroute.com.lk.